Venous Thromboembolism Prophylaxis in Thoracic Surgery

Jesse A. Schacht, Helene M. Sterbling, Virginia R. Litle

Abstract


Venous thromboembolism (VTE) is a dreaded post-operative complication in nearly all surgical specialties. There has been a decades-long effort to identify patients with high risk for post-operative VTE and determine the most appropriate course of action to prevent VTE occurrence. The 9th edition of the American College of Chest Physicians (ACCP) guidelines consider thoracic surgery patients to be at moderate risk for post-operative VTE. Despite recognition of post-operative VTE risk in thoracic surgery patients, there is a lack of consensus regarding the best practices to reduce VTE occurrence. VTE Risk Assessment Models (RAMs), including the Caprini RAM, have been developed outside of thoracic surgery to risk stratify patients for post-operative VTE and recommend appropriate prophylactic measures. Such interventions include early mobilization and inpatient mechanical compression devices, as well as chemoprophylaxis with unfractionated heparin and low-molecular-weight heparin, among other anticoagulants. Implementation of such interventions into general and vascular surgery have produced encouraging results with up to 84% reduction in VTE rates. Modification and application of existing RAMs in the thoracic surgery setting have shown promising preliminary results. Despite improvements achieved by implementing modified RAMs in thoracic surgery services at individual institutions, there are currently no field-specific guidelines to solidify practices nationwide. As a result, there remains considerable variability regarding patient screening, risk stratification, and VTE chemoprophylaxis practices. As most post-operative VTE occur after patient discharge, field-specific guidelines surrounding extended courses of chemoprophylaxis are needed. Large multicenter studies evaluating the implementation of specific VTE RAMs into thoracic surgery services are likely required before a standardized approach to VTE prevention can be achieved.


Keywords


venous thromoboembolism; VTE; DVT; PE; prophylaxis; thoracic surgery

Full Text:

PDF

References


Hachey KJ, Hewes PD, Porter LP, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg. 2016;151(1):37-44e1. doi:10.1016/j.jtcvs.2015.08.039.

Trinh VQ, Karakiewicz PI, Sammon J, et al. Venous thromboembolism after major cancer surgery: Temporal trends and patterns of care. JAMA Surg. 2014;149(1):43-49. doi:10.1001/jamasurg.2013.3172.

White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446-455. doi:10.1160/TH03-03-0152.

Agzarian J, Linkins LA, Schneider L, et al. Practice patterns in venous thromboembolism (VTE) prophylaxis in thoracic surgery: A comprehensive canadian delphi survey. J Thorac Dis. 2017;9(1):80-87. doi:10.21037/jtd.2017.01.38.

Raja S, Blackstone EH, Murthy SC. Caught between a rock and a hard place: Venous thromboembolism screening in high-risk patients. J Thorac Cardiovasc Surg. 2016;151(4):1000-1001. doi:10.1016/j.jtcvs.2015.12.023.

Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):227-277. doi:10.1378/chest.11-2297.

Nagahiro I, Andou A, Aoe M, et al. Intermittent pneumatic compression is effective in preventing symptomatic pulmonary embolism after thoracic surgery. Surg Today. 2004;34(1):6-10. doi:10.1007/s00595-003-2636-x.

Hewes PD, Hachey KJ, Zhang XW, et al. Evaluation of the Caprini model for venothromboembolism in esophagectomy patients. Ann Thorac Surg. 2015;100(6):2072-2078. doi:10.1016/j.athoracsur.2015.05.098.

Agzarian J, Hanna WC, Schneider L, et al. Postdischarge venous thromboembolic complications following pulmonary oncologic resection: An underdetected problem. J Thorac Cardiovasc Surg. 2016;151(4):992-999. doi:10.1016/j.jtcvs.2015.11.038.

Daddi G, Milillo G, Lupattelli L, et al. Postoperative pulmonary embolism detected with multislice computed tomography in lung surgery for cancer. J Thorac Cardiovasc Surg. 2006;132(1):197-198. doi:10.1016/j.jtcvs.2006.03.036.

Motykie GD, Zebala LP, Caprini JA, et al. A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis. 2000;9(3):253-262.

Jacobs B, Pannucci C. Scoring systems for estimating risk of venous thromboembolism in surgical patients. Semin Thromb Hemost. 2017;43(5):449-459. doi:10.1055/s-0036-1597288.

Mason DP, Quader MA, Blackstone EH, et al. Thromboembolism after pneumonectomy for malignancy: An independent marker of poor outcome. J Thorac Cardiovasc Surg. 2006;131(3):711-718. doi:10.1016/j.jtcvs.2005.10.027.

Merkow RP, Bilimoria KY, McCarter MD, et al. Post-discharge venous thromboembolism after cancer surgery: Extending the case for extended prophylaxis. Ann Surg. 2011;254(1):131-137. doi:10.1097/SLA.0b013e31821b98da.

Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009;339:b4583. doi:10.1136/bmj.b4583.

Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm. 2007;13(6):475-486. doi:2007(13)6: 475-486 [pii].

Dimick JB, Chen SL, Taheri PA, et al. Hospital costs associated with surgical complications: A report from the private-sector National Surgical Quality Improvement Program. J Am Coll Surg. 2004;199(4):531-537. doi:10.1016/j.jamcollsurg.2004.05.276.

Rathbun S. The surgeon general’s call to action to prevent deep vein thrombosis and pulmonary embolism. Circulation. 2009;119(15). doi:10.1161/CIRCULATIONAHA.108.841403.

Zwischenberger BA, Tzeng C-WD, Ward ND, et al. Venous thromboembolism prophylaxis for esophagectomy: A survey of practice patterns among thoracic surgeons. Ann Thorac Surg. 2016;101(2):489-494. doi:10.1016/j.athoracsur.2015.07.023.

Pannucci CJ, Barta RJ, Portschy PR, et al. Assessment of postoperative venous thromboembolism risk in plastic surgery patients using the 2005 and 2010 Caprini risk score. Plast Reconstr Surg. 2012;130(2):343-353. doi:10.1097/PRS.0b013e3182589e49.

Cassidy MR, Rosenkranz P, McAneny D. Reducing postoperative venous thromboembolism complications with a standardized risk-stratified prophylaxis protocol and mobilization program. J Am Coll Surg. 2014;218(6):1095-1104. doi:10.1016/j.jamcollsurg.2013.12.061.

Raja S, Idrees JJ, Blackstone EH, et al. Routine venous thromboembolism screening after pneumonectomy: The more you look, the more you see. J Thorac Cardiovasc Surg. 2016;152(2):524-532.e2. doi:10.1016/j.jtcvs.2016.03.097.

Litle VR. Don’t look now! Risk stratify first. J Thorac Cardiovasc Surg. 2016;152(2):533-534. doi:10.1016/j.jtcvs.2016.03.063.

Streiff MB, Carolan HT, Hobson DB, et al. Lessons from the Johns Hopkins Multi-Disciplinary Venous Thromboembolism (VTE) Prevention Collaborative. BMJ. 2012;344:e3935. doi:10.1136/BMJ.E3935.

Junqueira DR, Zorzela LM, Perini E. Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2017;2017(4). doi:10.1002/14651858.CD007557.pub3.

Eriksson BI, Borris LC, Friedman RJ, et al; for the RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.

Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594-604. doi:10.1056/NEJMoa0810773.

Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-2185. doi:10.1111/j.1538-7836.2007.02748.x.

Traynor K. Betrixaban approved as oral VTE preventive. Am J Heal Pharm. 2017;74(15)1118.

Pannucci CJ, Swistun L, MacDonald JK, et al. Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: A meta-analysis. Ann Surg. 2017;265(6):1094-1103. doi:10.1097/SLA.0000000000002126.




DOI: http://dx.doi.org/10.18103/imr.v4i3.686

Refbacks

  • There are currently no refbacks.
Copyright 2016. All rights reserved.